HGA
IOVA icon

Hobbs Group Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Hobbs Group Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-132
Closed -$1.24K – 374
2024
Q3 		$1.24K Hold
132
– – ﹤0.01% 603
2024
Q2 		$1.06K Buy
+132
New +$1.42K ﹤0.01% 567

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Hobbs Group Advisors's IOVA Position: Q4 2024 in Review

Hobbs Group Advisors sold out of Iovance Biotherapeutics (IOVA) in Q4 2024, closing a stake of 132 shares — an estimated $1.24K sold.

Hobbs Group Advisors first reported a position in IOVA in Q2 2024 and held it in 2 quarters. The position peaked at $1.24K in Q3 2024. 301 funds tracked by Wall St. Rank hold IOVA as of Q4 2024.

  • Hobbs Group Advisors reported no remaining Iovance Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Hobbs Group Advisors sold 132 Iovance Biotherapeutics shares in Q4 2024, an estimated $1.24K.
  • Hobbs Group Advisors first reported a position in Iovance Biotherapeutics in Q2 2024 and held it in 2 quarters.
  • Hobbs Group Advisors's Iovance Biotherapeutics position peaked at $1.24K in Q3 2024.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2024.

Based on Hobbs Group Advisors's 13F filing for Q4 2024, filed 12 Feb 2025.